Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 3/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | MMP9 | P14780 | 1/20 | 0.47 |
| ▸ | MMP14 | P50281 | 1/20 | 0.47 |
| ▸ | ESRRB | O95718 | 1/20 | 0.47 |
| ▸ | MME | P08473 | 1/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.45 |
| ▸ | CTSS | P25774 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4909047 | 1.00 | KMT2A (0.49) | KMT2AALDH1A1THRBCYP2C9CYP2C19 | |
| SCHEMBL1195693 | 1.00 | KMT2A (0.49) | KMT2AALDH1A1THRBCYP2C9CYP2C19 | |
| SCHEMBL3895456 | 0.92 | ALDH1A1 (0.45) | KMT2AALDH1A1THRBCYP2C9CYP2C19 | |
| SCHEMBL21246536 | 0.88 | ALDH1A1 (0.55) | KMT2AALDH1A1L3MBTL1SLC1A1CA1 | |
| SCHEMBL392233 | 0.85 | LMNA (0.54) | KMT2AALDH1A1HSD17B10L3MBTL1SLC1A1 | |
| SCHEMBL3034357 | 0.84 | SLC1A1 (0.55) | KMT2AALDH1A1CYP2C9CYP2C19SLC1A1 | |
| SCHEMBL800946 | 0.84 | SLC1A1 (0.55) | KMT2AALDH1A1CYP2C9CYP2C19SLC1A1 | |
| SCHEMBL7494382 | 0.84 | SLC1A1 (0.55) | KMT2AALDH1A1CYP2C9CYP2C19SLC1A1 | |
| SCHEMBL2405829 | 0.84 | TDP1 (0.44) | KMT2AALDH1A1MAPTL3MBTL1 | |
| SCHEMBL2405831 | 0.84 | TDP1 (0.44) | KMT2AALDH1A1MAPTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119431243-B | Deuterated huperzine A compound or pharmaceutically acceptable salt thereof as well as preparation method and application thereof | 万邦德制药集团有限公司 | 2025-06-10 | — | — | CN | disclosed |
| CN-119431243-A | Deuterated huperzine A compound or pharmaceutically acceptable salt thereof as well as preparation method and application thereof | 万邦德制药集团有限公司 | 2025-02-14 | — | — | CN | disclosed |
| US-20210380635-A1 | COMPOSITIONS AND METHODS FOR PROTEIN LABELING, MODIFICATION, ANALYSIS, AND TARGETED DELIVERY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-12-09 | — | — | US | disclosed |
| CN-110545854-A | method for renal function determination | MEDIBEACON INC | 2019-12-06 | — | — | CN | disclosed |
| CN-102010403-A | Total Synthesis of pladienolide B and pladienolide D | EISAI R&D MAN CO LTD | 2011-04-13 | — | — | CN | disclosed |
| CN-101282967-B | Total synthesis of pladienolide b and pladienolide D | EISAI R&D MAN CO LTD | 2011-01-26 | — | — | CN | disclosed |
| EP-1984377-A2 | INHIBITORS OF TNF ALPHA , PDE4 AND B-RAF, COMPOSITIONS THEREOF AND METHODS OF USE THEREWITH | Signal Pharmaceuticals LLC (US) | 2008-10-29 | — | — | EP | disclosed |
| CN-101282967-A | Total synthesis of pladienolide b and pladienolide D | EISAI R&D MAN CO LTD (JP) | 2008-10-08 | — | — | CN | disclosed |
| US-20080004271-A1 | Inhibitors of TNFalpha, PDE4 and B-RAF, compositions thereof and methods of use therewith | MCKENNA JEFFREY M | 2008-01-03 | — | — | US | disclosed |
| WO-2007084560-A2 | INHIBITORS OF TNFα, PDE4 AND B-RAF, COMPOSITIONS THEREOF AND METHODS OF USE THEREWITH | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-07-26 | — | — | WO | disclosed |
| US-4172958-A | Ethers of 2,6,10-trimethyl-undecan-1-ols | HOFFMANN-LA ROCHE INC. (US) | 1979-10-30 | — | — | US | disclosed |
| US-4169209-A | Ethers of 2,6-dimethyl-octane-1,8-diols | HOFFMANN-LA ROCHE INC. (US) | 1979-09-25 | — | — | US | disclosed |
| US-4163021-A | Synthesis of 2,6,10-trimethyl-undecan-1-ol | HOFFMANN-LA ROCHE INC. (US) | 1979-07-31 | — | — | US | disclosed |
| US-4151205-A | Synthesis of vitamin E | HOFFMAN-LA ROCHE INC. (US) | 1979-04-24 | — | — | US | disclosed |
| US-4140702-A | Process for producing vitamin E intermediate compounds | HOFFMANN-LA ROCHE INC. (US) | 1979-02-20 | — | — | US | disclosed |
| US-4140723-A | Intermediate compounds for producing vitamin E | HOFFMANN-LA ROCHE INC. (US) | 1979-02-20 | — | — | US | disclosed |
| US-4111961-A | Silicon ester of carboxylic acid | HOFFMANN-LA ROCHE INC. (US) | 1978-09-05 | — | — | US | disclosed |
| US-4107183-A | Synthesis of optically active carboxylic acid esters | HOFFMANN-LA ROCHE INC. (US) | 1978-08-15 | — | — | US | disclosed |
| US-4051153-A | Intermediates in the synthesis of vitamin E | HOFFMANN-LA ROCHE INC. (US) | 1977-09-27 | — | — | US | disclosed |
| US-4041058-A | Synthesis of 2,6,10-trimethyl-undecan-1-ol | HOFFMANN-LA ROCHE INC. (US) | 1977-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004271-A1 | Inhibitors of TNFalpha, PDE4 and B-RAF, compositions thereof and methods of use therewith | PDE4A, PDE4B, BRAF | KMT2A 3422/4885ALDH1A1 1662/4885THRB 1168/4885 |
| US-20210380635-A1 | COMPOSITIONS AND METHODS FOR PROTEIN LABELING, MODIFICATION, ANALYSIS, AND TARGETED DELIVERY | PTMS, SRMS, CHAMP1 | KMT2A 3048/4885ALDH1A1 3049/4885THRB 3964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.